Skip to Content
Merck
  • The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells.

The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells.

Biochemical and biophysical research communications (2014-06-08)
Orit Uziel, Gil Kanfer, Einat Beery, Dana Yelin, Daniel Shepshelovich, Mary Bakhanashvili, Jardena Nordenberg, Meir Lahav
ABSTRACT

Treatment with erythropoietin (EPO) in several cancers is associated with decreased survival due to cancer progression. Due to the major importance of telomerase in cancer biology we hypothesized that some of these effects may be mediated through EPO effect on telomerase. For this aim we explored the possible effects of EPO on telomerase regulation, cell migration and chemosensitivity in non-erythroid malignant and non-malignant cells. Cell proliferation, telomerase activity (TA) and cell migration increased in response to EPO. EPO had no effect on cancer cells sensitivity to cisplatinum and on the cell cycle status. The inhibition of telomerase modestly repressed the proliferative effect of EPO. Telomere shortening caused by long term inhibition of the enzyme abolished the effect of EPO, suggesting that EPO effects on cancer cells are related to telomere dynamics. TA was correlated with the levels of Epo-R. The increase in TA was mediated post-translationally through the Lyn-Src and not the canonical JAK2 pathway.

MATERIALS
Product Number
Brand
Product Description

Erythropoietin, BRP, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
IL-3 human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)
Sigma-Aldrich
IL-3 from mouse, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)